[Therapy of primary hyperlipoproteinemia types IIa, IIb and IV using beta pyridylcarbinol Study on three phases under ambulatory conditions].
D000328:Adult; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006949:Hyperlipidemias / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D000432:Methanol; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010919:Placebos; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D008074:Lipoproteins; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010919:Placebos; D011725:Pyridines; D014280:Triglycerides; D002784:Cholesterol; D000432:Methanol
behandlung primärer Hyperlipoproteinämien der Typen IIa, IIb and IV mit beta-Pyridylcarbinol. Eine Dreiphasenstudie unter ambulanten Bedingungen.